Levetiracetam Tablet, Extended Release
Product Images NDC 68001-114

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 68001-114). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Molecular Structure-levetiracetam (0ec567ac 9f44 4b97 92af 1bb615d146fb 01)

Chemical structure of levetiracetam, showing the molecular arrangement of atoms including the pyrrolidone ring and side chains characteristic of this active ingredient.*

FDA Label Image

Figure 1 (0ec567ac 9f44 4b97 92af 1bb615d146fb 02)

A bar chart showing percentage of patients on the vertical axis, comparing three groups: placebo (7.4%, N=95), immediate-release levetiracetam 1000 mg/day (37.1%, N=97), and immediate-release levetiracetam 3000 mg/day (39.6%, N=101). Statistically significant differences versus placebo are indicated by asterisks on the levetiracetam groups.*

FDA Label Image

Figure 2 (0ec567ac 9f44 4b97 92af 1bb615d146fb 03)

A bar chart comparing the percentage of patients in three groups: placebo, immediate-release levetiracetam 1000 mg/day, and immediate-release levetiracetam 2000 mg/day. The percentages shown are 6.3% for placebo, 20.8% for 1000 mg/day, and 35.2% for 2000 mg/day, with statistical significance markers for the levetiracetam groups versus placebo.*

FDA Label Image

Figure 3 (0ec567ac 9f44 4b97 92af 1bb615d146fb 04)

Bar chart comparing the percentage of patients experiencing an effect between placebo and immediate-release levetiracetam 3000 mg/day. The placebo group (N=104) shows 14.4% of patients, while the levetiracetam group (N=180) shows 39.4%, marked as statistically significant versus placebo with an asterisk. The y-axis represents percentage of patients from 0% to 45%.*

FDA Label Image

Figure 4 (0ec567ac 9f44 4b97 92af 1bb615d146fb 05)

Bar chart showing the percentage of patients responding for two groups: Placebo (N=97) at 19.6% and Immediate-release levetiracetam (N=101) at 44.6%. The chart indicates a statistically significant difference favoring the immediate-release levetiracetam group compared to placebo.*

FDA Label Image

Levetiracetam Er 500mg (Rev 04/16)

Label for Levetiracetam Extended-Release Tablets USP 500 mg by BluePoint Laboratories. The film-coated tablet is for oral use with once-daily dosing. The label includes storage instructions, dispensing requirements, and manufacturer information, and states the package contains 60 tablets.*

FDA Label Image

Levetiracetam Er 750mg Rev 04/17 (Image 02)

Label for Levetiracetam Extended-Release Tablets USP, 750 mg, manufactured by BluePoint Laboratories. The label is for oral extended-release tablets, packaged with 60 tablets per bottle. It includes dosage information, storage instructions, and a barcode. The label also indicates the drug is for prescription use only and highlights the 750 mg strength in bold orange text.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.